Cargando…
Quinolone Allergy
Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-r...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789783/ https://www.ncbi.nlm.nih.gov/pubmed/31330937 http://dx.doi.org/10.3390/pharmacy7030097 |
_version_ | 1783458693697765376 |
---|---|
author | McGee, Edoabasi U. Samuel, Essie Boronea, Bernadett Dillard, Nakoasha Milby, Madison N. Lewis, Susan J. |
author_facet | McGee, Edoabasi U. Samuel, Essie Boronea, Bernadett Dillard, Nakoasha Milby, Madison N. Lewis, Susan J. |
author_sort | McGee, Edoabasi U. |
collection | PubMed |
description | Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available. |
format | Online Article Text |
id | pubmed-6789783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67897832019-10-16 Quinolone Allergy McGee, Edoabasi U. Samuel, Essie Boronea, Bernadett Dillard, Nakoasha Milby, Madison N. Lewis, Susan J. Pharmacy (Basel) Review Quinolones are the second most common antibiotic class associated with drug-induced allergic reactions, but data on quinolone allergy are scarce. This review article discusses the available evidence on quinolone allergy, including prevalence, risk factors, diagnosis, clinical manifestations, cross-reactivity, and management of allergic reactions. Although the incidence of quinolone allergy is still lower than beta-lactams, it has been increasingly reported in recent decades, most likely from its expanded use and the introduction of moxifloxacin. Thorough patient history remains essential in the evaluation of quinolone allergy. Many diagnostic tools have been investigated, but skin tests can yield false-positive results and in vitro tests have not been validated. The drug provocation test is considered the test of choice to confirm a quinolone allergy but is not without risk. Evidence regarding cross-reactivity among the quinolones is limited and conflicting. Quinolone allergy can be manifested either as an immediate or delayed reaction, but is not uniform across the class, with moxifloxacin posing the highest risk of anaphylaxis. Quinolone should be discontinued when an allergic reaction occurs and avoided in future scenarios, but desensitization may be warranted if no alternatives are available. MDPI 2019-07-19 /pmc/articles/PMC6789783/ /pubmed/31330937 http://dx.doi.org/10.3390/pharmacy7030097 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review McGee, Edoabasi U. Samuel, Essie Boronea, Bernadett Dillard, Nakoasha Milby, Madison N. Lewis, Susan J. Quinolone Allergy |
title | Quinolone Allergy |
title_full | Quinolone Allergy |
title_fullStr | Quinolone Allergy |
title_full_unstemmed | Quinolone Allergy |
title_short | Quinolone Allergy |
title_sort | quinolone allergy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789783/ https://www.ncbi.nlm.nih.gov/pubmed/31330937 http://dx.doi.org/10.3390/pharmacy7030097 |
work_keys_str_mv | AT mcgeeedoabasiu quinoloneallergy AT samuelessie quinoloneallergy AT boroneabernadett quinoloneallergy AT dillardnakoasha quinoloneallergy AT milbymadisonn quinoloneallergy AT lewissusanj quinoloneallergy |